21,717 Shares in Glaukos Corporation $GKOS Acquired by Zhang Financial LLC

Zhang Financial LLC purchased a new stake in Glaukos Corporation (NYSE:GKOS) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 21,717 shares of the medical instruments supplier’s stock, valued at approximately $1,771,000.

Several other institutional investors also recently modified their holdings of GKOS. UMB Bank n.a. lifted its position in Glaukos by 102.6% during the third quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 158 shares during the last quarter. REAP Financial Group LLC bought a new position in shares of Glaukos during the 3rd quarter valued at about $40,000. AlphaQuest LLC boosted its stake in Glaukos by 5,754.5% in the second quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock worth $67,000 after buying an additional 633 shares in the last quarter. SBI Securities Co. Ltd. raised its stake in shares of Glaukos by 42.9% during the third quarter. SBI Securities Co. Ltd. now owns 1,205 shares of the medical instruments supplier’s stock worth $98,000 after acquiring an additional 362 shares in the last quarter. Finally, Smartleaf Asset Management LLC grew its holdings in shares of Glaukos by 16.2% during the 2nd quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 136 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Stephens boosted their price target on shares of Glaukos from $115.00 to $145.00 and gave the stock an “overweight” rating in a research note on Friday, January 2nd. Stifel Nicolaus boosted their target price on Glaukos from $115.00 to $160.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. UBS Group raised their price target on Glaukos from $140.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, December 23rd. Wells Fargo & Company boosted their price objective on Glaukos from $122.00 to $135.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $138.00 price objective on shares of Glaukos in a research note on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $133.69.

Glaukos Trading Up 1.7%

GKOS opened at $121.25 on Thursday. Glaukos Corporation has a one year low of $73.16 and a one year high of $130.23. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.69 and a quick ratio of 4.06. The business has a 50 day simple moving average of $115.75 and a two-hundred day simple moving average of $99.63. The firm has a market capitalization of $7.04 billion, a price-to-earnings ratio of -37.19 and a beta of 0.70.

Glaukos (NYSE:GKOS) last posted its earnings results on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.06). The business had revenue of $143.12 million for the quarter, compared to analysts’ expectations of $132.16 million. Glaukos had a negative net margin of 36.99% and a negative return on equity of 7.00%. Glaukos’s quarterly revenue was up 35.6% on a year-over-year basis. During the same period last year, the firm posted ($0.40) earnings per share. Analysts predict that Glaukos Corporation will post -1.08 EPS for the current year.

Insider Buying and Selling at Glaukos

In other Glaukos news, Director Marc Stapley sold 15,000 shares of the company’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $127.71, for a total value of $1,915,650.00. Following the completion of the transaction, the director directly owned 37,449 shares in the company, valued at approximately $4,782,611.79. This represents a 28.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Joseph E. Gilliam sold 10,498 shares of Glaukos stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $127.68, for a total transaction of $1,340,384.64. Following the sale, the chief operating officer directly owned 92,366 shares in the company, valued at $11,793,290.88. The trade was a 10.21% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 325,000 shares of company stock worth $37,739,259. 5.80% of the stock is owned by corporate insiders.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.